Cardiometabolic Disease and COVID-19: Risk, Treatment and Trials

Published: 13 July 2020

  • Views:

    Views Icon 89
  • Likes:

    Heart Icon 1

Overview

Full programme

  • Views:

    Views Icon 89
  • Likes:

    Heart Icon 1

Overview

In this series, Mikhail Kosiborod and Hertzel Gerstein discuss the effects of Covid-19 and metabolic disease, early treatment with metabolic therapies and the Phase III DARE-19 Trial looking at dapagliflozin in Covid-19 patients.

Recorded remotely from Hamilton and Kansas City, 2020.

This discussion was supported by an unrestricted educational grant from Novo Nordisk.

Series overview

Part 1

The Effect of COVID and Metabolic Disease and Early Treatment

Dr Mikhail N Kosiborod (Saint Luke's America Heart Institute, Kansas City, US) joins Prof Hertzel Gerstein (McMaster University, Hamilton, ON, CA) to discuss the current landscape of cardiometabolic therapies for COVID-19. Dr Kosiborod talks about the cardiometabolic risk factors for death in people who are hospitalised with COVID-19.

1 session

  • The Effect of COVID and Metabolic Disease and Early Treatment

    Watch now

Part 2

Metabolic Therapy Treatments

Prof Gerstein (McMaster University, Hamilton, ON, CA) and Dr Kosiborod (Saint Luke's America Heart Institute, Kansas City, US) discuss whether organ protection can complement other treatments for COVID-19. Dr Kosiborod discusses DARE-19, an international study evaluating the effect of dapagliflozin versus placebo in addition to background therapy, in reducing disease progression, complications and all-cause mortality.

1 session

Part 3

Phase III DARE-19 Trial

Dr Mikhail N Kosiborod (Saint Luke's America Heart Institute, Kansas City, US) talks about the DARE-19 trial, an international study evaluating the effect of dapagliflozin versus placebo in addition to background therapy, in reducing disease progression, complications, and all-cause mortality.

1 session

Faculty biographies